Immunology Investor Event

We are just at the beginning of our journey... DUPIXENT (dupilumab) Atopic Dermatitis Adult 18+ Asthma Adult /Adol 12+ Atopic Dermatitis Adolescent 12+ CRSWNP Adult 18+ Atopic Dermatitis Ped 6-11 ୩ Asthma Ped 6-11 sanofi Today CIndU-COLD Adult/Adol 12+ CSU Adult/Adol 12+ EoE Ped 1-11 Prurigo Nodularis Adult 18+ EoE Adult / Adol 12+ Atopic Dermatitis Infant 6 mo-5Y DEN DEN EN 57 Bullous Pemphigoid Adult 18+ AFRS Adult / Ped 6+ COPD Adult 18+ CRSSNP Adult / Adol 12+ CPUO Adult 18+ by 2025 Approved Under regulatory review / submitted Investigational indications 1. Sanofi epidemiology estimates ...opportunity to add at least 1.5 million¹ of eligible patients 25 Immunology Investor Event

View entire presentation